Ekimas Corp (ASNB) SEC Filing 10-Q Quarterly Report for the period ending Thursday, June 30, 2022

SEC Filings

ASNB Quarterly Reports

Advansource Biomaterials Corp

CIK: 1499961 Ticker: ASNB
Cover - shares
3 Months Ended
Jun. 30, 2022
Aug. 26, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateJun. 30, 2022 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--03-31 
Entity File Number0-28034 
Entity Registrant NameEKIMASCORPORATION 
Entity Central Index Key0001011060 
Entity Tax Identification Number04-3186647 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One3651 Lindell Road 
Entity Address, Address Line TwoSuite D565 
Entity Address, City or TownLas Vegas 
Entity Address, State or ProvinceNV 
Entity Address, Postal Zip Code89103 
City Area Code(424) 
Local Phone Number256-8560 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companytrue 
Entity Common Stock, Shares Outstanding 5,681,248

View differences made from one quarter to another to evaluate Advansource Biomaterials Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advansource Biomaterials Corp.


Assess how Advansource Biomaterials Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advansource Biomaterials Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Advansource Biomaterials Corp provided additional information to their SEC Filing as exhibits

Ticker: ASNB
CIK: 1011060
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-024151
Submitted to the SEC: Fri Aug 26 2022 3:12:27 PM EST
Accepted by the SEC: Fri Aug 26 2022
Period: Thursday, June 30, 2022
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: